Media coverage about Regenxbio (NASDAQ:RGNX) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regenxbio earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.2148101386345 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s scoring:
- Mizuho Initiates Coverage on Regenxbio (RGNX) (americanbankingnews.com)
- Regenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis (finance.yahoo.com)
- BidaskClub Upgrades Regenxbio (RGNX) to Buy (americanbankingnews.com)
- Regenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD (streetinsider.com)
- REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD (finance.yahoo.com)
Several research firms have recently weighed in on RGNX. BidaskClub downgraded shares of Regenxbio from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Mizuho began coverage on shares of Regenxbio in a research note on Monday. They set a “neutral” rating and a $28.00 price objective for the company. Chardan Capital boosted their price objective on shares of Regenxbio from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $40.63.
In other Regenxbio news, insider Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $27.33, for a total value of $273,300.00. Following the completion of the transaction, the insider now owns 248,530 shares of the company’s stock, valued at approximately $6,792,324.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Vittal Vasista sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief financial officer now directly owns 87,277 shares of the company’s stock, valued at approximately $2,618,310. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 94,000 shares of company stock valued at $2,879,096. 17.00% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Regenxbio (RGNX) Share Price” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2018/02/15/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-regenxbio-rgnx-share-price.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.